Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05658302 · ClinicalTrials.gov registry record

Circuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst

A clinical trial of Parkinson Disease, sponsored by University of Minnesota.

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT05658302: Recruiting study of Parkinson Disease, sponsored by University of Minnesota.

NCT05658302 is a study of Parkinson Disease that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 30 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05658302, a study of Parkinson Disease, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

This study will help us better understand how the brain works in people with Parkinson's disease (PD). PD is a brain disease that gets worse over time, and affects over 10 million people world-wide. A common treatment for PD is Deep Brain Stimulation (DBS). To improve DBS therapy for PD, we need a deeper understanding of how the different parts of the brain work together in PD, and how this relates to movement and thinking problems that people with PD experience. We may be able to use the results of this study to improve DBS treatments in the future.

Primary Outcome

reach-related modulation in beta/HFO power in DBS lead LFPs across OFF, DBS, L-dopa, and DBS+L-dopa conditions.

Conditions Studied

Parkinson Disease

Study Locations (1)

Minnesota

  • University Of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-03-28
Est. Completion 2028-03-01
University of Minnesota

966 total trials

What NCT05658302 shows while recruiting

NCT05658302 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05658302 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05658302 about?

NCT05658302 is a clinical study titled "Circuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst". This study will help us better understand how the brain works in people with Parkinson's disease (PD). PD is a brain disease that gets worse over time, and affects over 10 million people world-wide. A common treatment for PD is Deep Brain Stimulation (DBS). To improve DBS therapy for PD, we need a d...

What is the current status of trial NCT05658302?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-03-28. Estimated completion is 2028-03-01.

What conditions does trial NCT05658302 study?

This clinical trial studies the following conditions: Parkinson Disease.

Who is sponsoring clinical trial NCT05658302?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05658302 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05658302's enrollment target sits among peer trials

30 209th of 297 higher than 80 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05658302

Source: ClinicalTrials.gov NCT05658302, the US trial registry maintained by the National Library of Medicine. NCT05658302 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.